Objective-To examine the direct effect of apolipoprotein CIII (apoCIII) on adipokine expressions that are involved in obesity, insulin resistance, or metabolic syndrome. Methods and Results-ApoCIII in triglyceride-rich lipoproteins is elevated in patients with obesity, insulin resistance, or metabolic syndrome. Its level is also associated with proinflammatory adipokines. Fully differentiated mouse 3T3L1 adipocytes were incubated with apoCIII. ApoCIII activated nuclear factor B of 3T3L1 adipocytes and induced the expression of monocyte chemoattractant protein (MCP) 1 and interleukin (IL) 6. ApoCIII also activated extracellular signal-regulated kinase and p38. Mitogen-activated protein kinase kinase (MEK)-1 inhibitor PD98059, but not p38 inhibitor SB203580, inhibited apoCIII-induced upregulation of MCP-1 and IL-6. Previously, it was shown that apoCIII activates proinflammatory signals through toll-like receptor (TLR) 2. TLR2-blocking antibody abolished activation of nuclear factor B and extracellular signal-regulated kinase induced by apoCIII and inhibited apoCIII-induced upregulation of MCP-1 and IL-6. ApoCIII also reduced adiponectin expression of 3T3L1 adipocytes, which was recovered by TLR2-blocking antibody. ApoCIII induced the expression of MCP-1 and IL-6 in TLR2-overexpressed human embryonic kidney 293 cells but not wild-type human embryonic kidney 293 cells without TLR2. ApoCIII induced the expression of MCP-1 and IL-6 and decreased adiponectin expression in white adipose tissue of wild-type mice but not of TLR2-deficient mice in vivo. Conclusion-ApoCIII may activate extracellular signal-regulated kinase and nuclear factor kB through TLR2 and induce proinflammatory adipokine expression in vitro and in vivo. Thus, apoCIII links dyslipidemia to inflammation in adipocytes, which, in turn, may contribute to atherosclerosis. Key Words: apolipoproteins Ⅲ atherosclerosis Ⅲ cytokines Ⅲ immune system Ⅲ signal transduction A polipoprotein CIII (apoCIII) is a small protein that resides on the surface of very-low-density lipoprotein (VLDL) and LDL. ApoCIII inhibits clearance from plasma of VLDL and LDL 1-5 and causes accumulation of atherogenic remnant lipoproteins and dense LDL in plasma. [3] [4] [5] [6] ApoCIIIcontaining lipoproteins are a prominent feature of hypertriglyceridemia. 7 ApoCIII in VLDL and LDL strongly predicts coronary heart disease in several populations. 8 -10 Therefore, the association of apoCIII with cardiovascular disease has been commonly attributed to its inhibitory effect on lipoprotein catabolism. However, it was recently shown that apoCIII has direct proinflammatory and atherogenic effects on vascular wall cells. ApoCIII activated both peripheral monocytes and vascular endothelial cells and enhanced their adhesive interactions. 11,12 These findings suggest that direct proinflammatory effects on vascular cells may be responsible for the positive correlation between apoCIII and cardiovascular disease risk in population studies.
A polipoprotein CIII (apoCIII) is a small protein that resides on the surface of very-low-density lipoprotein (VLDL) and LDL. ApoCIII inhibits clearance from plasma of VLDL and LDL [1] [2] [3] [4] [5] and causes accumulation of atherogenic remnant lipoproteins and dense LDL in plasma. [3] [4] [5] [6] ApoCIIIcontaining lipoproteins are a prominent feature of hypertriglyceridemia. 7 ApoCIII in VLDL and LDL strongly predicts coronary heart disease in several populations. 8 -10 Therefore, the association of apoCIII with cardiovascular disease has been commonly attributed to its inhibitory effect on lipoprotein catabolism. However, it was recently shown that apoCIII has direct proinflammatory and atherogenic effects on vascular wall cells. ApoCIII activated both peripheral monocytes and vascular endothelial cells and enhanced their adhesive interactions. 11, 12 These findings suggest that direct proinflammatory effects on vascular cells may be responsible for the positive correlation between apoCIII and cardiovascular disease risk in population studies.
Insulin resistance stimulates hepatocyte apoCIII production. 13 Indeed, several clinical studies reported that the plasma apoCIII level is elevated in patients with metabolic syndrome 14 and is associated with body mass index and homeostasis model assessment of insulin resistance. 15, 16 Recently, it was reported that apoCIII caused insulin resistance in endothelial cells in vitro and that it inhibited endotheliumdependent vasodilatation in vivo. 17 Moreover, Salerno et al 18 reported that overexpression of apoCIII increased dietinduced obesity in mice. These findings suggest that increased apoCIII is not only a clinical manifestation of metabolic disorders but also may deteriorate morbid conditions of metabolic disorders.
Metabolic syndrome is characterized by increased visceral adiposity. Gene expressions of numerous inflammatory me-diators, called adipokines, are increased in adipose tissue during the development of visceral adiposity. These proinflammatory adipokines cause inflammation, contributing to atherosclerosis. Recent clinical studies reported that plasma interleukin (IL) 6 was significantly correlated with apoCIII independently of triglyceride, VLDL, and remnant lipoprotein (RLP) cholesterol 16 and that plasma adiponectin was inversely correlated with apoCIII. 16, 19 However, the casual relationship between apoCIII and adipokines has not been studied. The expression of adipokines is also affected by inflammatory mediators and related signaling pathways, including nuclear factor (NF) B 20 ; and apoCIII activates these inflammatory signaling pathways in several types of cells. 12, 21 Thus, we hypothesized that apoCIII in VLDL directly modulates the expression of adipokines. The present study was designed to examine this hypothesis and, if true, to elucidate its cellular mechanism.
Methods

Reagents
Human apos and anti-apo antibodies were purchased. Endotoxin levels in apos measured using a Limulus amebocyte lysate chromogenic test were Ͻ0.03 EU/mL. Free fatty acid levels in apos determined enzymatically were Ͻ20 nmol/L, which is much lower than is reported to induce inflammation in endothelial cells. In some experiments, apoCIII was incubated with inert acrylic beads attached to lipase of Candida cylindracea (immobilized lipase), as previously described. 22 After the beads were removed by centrifugation, the effects of apoCIII were assayed using 3T3L1 adipocytes.
Cell Culture
Mouse 3T3L1 preadipocytes were purchased from American Type Culture Collection, Manassas, Va. The differentiation of 3T3L1 preadipocytes to adipocytes was described elsewhere. 23 Wild-type human embryonic kidney (HEK) 293 cells and HEK293 cells stably transfected with human toll-like receptor (TLR) 2 were purchased.
Animals
Six-week-old male C57BL/6 (wild-type) mice (Oriental Yeast, Tokyo, Japan) or TLR2-deficient mice consumed a standard diet. Food and water were provided ad libitum. Then, wild-type and TLR2-deficient mice were administered apoCIII, 400 g/body, or PBS, IP 24 once per day. After 1 week, fasting plasma was collected for ELISA and metabolic parameters; and epididymal white adipose tissue (WAT) was dissected for RT-PCR and immunoblotting. In some experiments, the stromal vascular fraction and the adipocyte fraction were separated from WAT, as previously described. 25 All animal experiments were conducted in accordance with the guidelines of the Tokyo Medical and Dental University Committee on Animal Research, Tokyo.
Lipoprotein Preparation
Blood was drawn in tubes containing EDTA from 10 healthy volunteers after 12 hours of fasting. The subjects were not taking cardiovascular medications, antioxidants, or estrogen. VLDL (dϽ1.006) with apoIII (VLDL CIIIϩ) or without apoCIII (VLDL CIIIϪ) was isolated from plasma, as previously described. 11 The protocol of this study complied with the guidelines for the conduct of research involving human subjects by the Committee on Human Research at Tokyo Medical and Dental University. Endotoxin levels in VLDL preparations were Ͻ0.03 EU/mL.
RT-PCR and ELISA
Total RNA was isolated from 3T3L1 adipocytes or mice WAT using a kit (RNeasy mini kit) and then converted to cDNA using a reverse-transcript method with transcriptase (Superscript III RNase H Reverse Transcriptase). Real-time PCR was performed using primer sets (supplemental Table I ; available online at http://atvb. ahajournals.org) with a sequence detection system (ABI PRISM 7900HT). Relative mRNA transcript levels were calculated using the comparative computed tomographic method, which is based on the difference in cycle threshold values between the target mRNA and ␤-actin, used as an internal control.
Concentrations of monocyte chemoattractant protein (MCP) 1, IL-6, and adiponectin in the culture medium of 3T3L1 adipocytes or in the plasma of mice were determined by an ELISA kit.
Immunoblotting
After treatment with apoCIII or VLDL fractions, 3T3L1 adipocyte lysates or mice WAT lysates were prepared as previously described. 12 Lysate was assayed with immunoblotting using antibodies to antiphosphorylated p65 NF-B antibody, antiphosphorylated extracellular signal-regulated kinase (ERK) antibody, antiphosphorylated p38 antibody, or anti-CD68 antibody.
Immunofluorescence Microscopy
For NF-B p65 staining, 3T3L1 adipocytes were fixed with 4% formaldehyde for 30 minutes, then treated with 0.05% Triton X-100 for 5 minutes. The cells were incubated with fluorescein isothiocyanate-conjugated NF-B p65 antibody (1:200) for 45 minutes. The cells were rinsed and mounted onto slides, then analyzed and imaged using a fluorescent microscope with a 400-fold magnification. A, 3T3L1 adipocytes were incubated with apoCIII at 100 g/mL for the indicated hours. *PϽ0.05 vs 0 hours. B, 3T3L1 adipocytes were incubated with apoCIII at the indicated concentrations for 8 hours. *PϽ0.05 vs 0 g/mL. C, 3T3L1 adipocytes were incubated with apoCIII (100 g/mL for 8 hours) or PBS (control). *PϽ0.05 vs control.
Abe et al ApoCIII Modulates Adipokine Expressions 2243
R E T R A C T E D A R T I C L E
This article was retracted in March 2012
Statistical Analysis
Data are expressed as the meanϮSE. Statistical analysis was performed using a Student t test or ANOVA. PϽ0.05 was considered statistically significant.
Results
ApoCIII Induces MCP-1 and IL-6 Expression in 3T3L1 Adipocytes
We first examined the direct effect of apoCIII on proinflammatory adipokine expression in 3T3L1 adipocytes. ApoCIII increased MCP-1 and IL-6 mRNA levels of 3T3L1 adipocytes in a time-and concentration-dependent manner ( Figure  1A and B). ApoCIII significantly increased the concentrations of MCP-1 and IL-6 in the culture media ( Figure 1C ). In contrast, apoCI, apoCII, or apoE did not induce the expression of these adipokines (supplemental Figure IA) . Pretreatment of apoCIII with apoCIII-blocking antibody abolished its effect (supplemental Figure IB) . Then, we treated apoCIII with immobilized lipase that removed the TLR2-stimulating activity of lipopeptides to exclude the possibility that the effect of apoCIII is attributable to contamination with bacterial lipopeptides. The treatment did not affect the capacity of apoCIII to modulate adipokine expressions in 3T3L1 adipocytes (supplemental Figure IC and D) .
ApoCIII Activates NF-kB in 3T3L1 Adipocytes
NF-B plays an important role in the upregulation of MCP-1 and IL-6 in adipocytes. 26 It was previously reported that apoCIII alone or in apoB lipoproteins activates NF-B in several types of cells. 12, 21, 24 In the present study, apoCIII induced the phosphorylation of NF-B p65 in 3T3L1 adipocytes. ApoCIII also induced translocation of NF-B p65 into the nucleus, suggesting its activation (Figure 2A and B). ApoCIII-blocking antibody abolished its effect (Figure 2A) . Pretreatment of 3T3L1 adipocytes with NF-B inhibitor peptide SN50 partially inhibited apoCIII-induced upregulation of MCP-1 and IL-6, whereas scramble peptide for SN50 had no effect ( Figure 2C ). SN50 also decreased the release of these adipokines into the culture media ( Figure 2D ). Treatment of apoCIII with immobilized lipase did not affect its stimulation of phosphorylation of p65 (supplemental Figure IE ).
ApoCIII Activates Mitogen-Activated Protein Kinases in 3T3L1 Adipocytes
Mitogen-activated protein (MAP) kinase pathways play an important role in proliferation and differentiation of adipocytes. Moreover, the activation of ERK is involved in increased production of MCP-1 in 3T3L1 adipocytes. 27 Thus, we examined the involvement of MAP kinases in apoCIIIinduced MCP-1 and IL-6 upregulation in 3T3L1 adipocytes. ApoCIII increased phosphorylation of extracellular signalregulated kinase-1 (ERK1) and p38 (to a lesser extent), suggesting their activation ( Figure 3A ). ApoCIII-blocking antibody abolished this activation (data not shown). c-Jun N-terminal kinase (JNK) was not activated by apoCIII (Figure 3A) . Pretreatment of 3T3L1 adipocytes with MEK1 inhibitor PD98059 attenuated apoCIII-induced upregulation of MCP-1 and IL-6, whereas p38 inhibitor SB203580 did not affect their expressions ( Figure 3B ). PD98059 also inhibited the release of these adipokines into the culture media ( Figure  3C ). Because PD98059 did not affect apoCIII-induced NF-B activation (data not shown), these results suggest that apoCIII also upregulates adipokines through ERK, independently of its activation of NF-B. 
TLR2 Mediates ApoCIII-Induced MCP-1 and IL-6 Expressions in 3T3L1 Adipocytes
It was previously reported that TLR2 mediates proinflammatory signaling pathways of apoCIII in human peripheral monocytes. 24 Because adipocytes also express TLR families, we examined the involvement of TLRs in adipokine expression. TLR2-blocking antibody, but not TLR4-blocking antibody or isotype IgG, inhibited apoCIII-induced NF-B activation ( Figure 4A and B). TLR2-blocking antibody also inhibited apoCIII-induced ERK activation ( Figure 4C ). TLR2-blocking antibody completely blocked apoCIIIinduced MCP-1 and IL-6 upregulation ( Figure 4D and E). We confirmed that a TLR2 agonist, lipoteichoic acid, induced MCP-1 and IL-6 upregulation, which was inhibited by TLR2 antibody, but not TLR4 antibody (supplemental Figure II) . Taken together, these results indicate that TLR2 signaling is an upstream key pathway by which apoCIII activates NF-B and ERK and upregulates adipokines in 3T3L1 adipocytes.
ApoCIII Decreases Adiponectin in 3T3L1 Adipocytes
We also examined the effect of apoCIII on adiponectin expression because proinflammatory signaling downregulates adiponectin. ApoCIII reduced adiponectin and peroxisome proliferator-activated receptor (PPAR)-␥ expression and adiponectin protein release into the media ( Figure 5A and B), which were recovered by SN50 and TLR2-blocking antibody ( Figure 5C and D). These results suggest that apoCIII downregulates adiponectin via a TLR2-NF-B signaling pathway.
ApoCIII Modulates Adipokine Expression in Human TRL2-Overexpressed HEK293 Cells
We further examined the role of TLR2 in adipokine production. We used wild-type HEK293 cells that do not express TLR2. ApoCIII did not change the expression of MCP-1 and adiponectin in wild-type HEK293 cells. However, when TRL2 was overexpressed in HEK293 cells, apoCIII significantly induced MCP-1 expression ( Figure 6A ) and decreased adiponectin expression ( Figure 6B ). TLR2-blocking antibody abolished the effects of apoCIII ( Figure 6A and B). In accordance with these results, apoCIII activated NF-B only, of TLR2-overexpressed HEK293 cells, which was inhibited by pretreatment with TLR2-blocking antibody ( Figure 6C ).
ApoCIII-Rich VLDL Modulates Adipokine Production in 3T3L1 Adipocytes
Because apoCIII resides on VLDL in the fasting and postprandial state, we tested whether apoCIII-rich VLDL (VLDL CIIIϩ) modulates adipokine expression. VLDL CIIIϩ induced the expression of MCP-1 and IL-6 and decreased the expression of adiponectin (supplemental Figure IIIA) . Pretreatment of VLDL CIIIϩ with apoCIII-blocking antibody attenuated these effects. ApoCIII-deficient VLDL (VLDL CIIIϪ) also increased MCP-1 and IL-6 expression. However, its effects were much smaller than those of VLDL CIIIϩ. 
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VLDL CIIIϪ did not affect adiponectin expression (supplemental Figure IIIB ). TLR2-blocking antibody treatment abolished the effect of VLDL CIIIϩ on these adipokine expressions (supplemental Figure IVC and D) .
ApoCIII Modulates Adipokine Production In Vivo
Finally, we examined whether apoCIII modulates adipokine expression in vivo. ApoCIII increased the expression of MCP-1 and IL-6 of WAT of wild-type mice and increased their plasma levels (supplemental Figure IVA and B) . In contrast, apoCIII decreased WAT adiponectin expression and its plasma level (supplemental Figure IVC and D) . The effects of apoCIII on adipokine expressions were not observed in WAT of TLR2-deficient mice (supplemental Figure  IVA-D) . These results suggest that apoCIII modulates adipokine expression through TLR2. Recent studies revealed that macrophages that infiltrated into the stromal vascular fraction of WAT are another source of proinflammatory adipokines, such as MCP-1. As shown in supplemental Figure IVE , apoCIII increased macrophage content in WAT of wild-type mice, as assessed by CD68. ApoCIII also increased MCP-1 expression in the stromal vascular fraction and adipocyte fraction of WAT (supplemental Figure IVF) . These results suggest that apoCIII treatment induced the recruitment of macrophages into WAT through MCP-1, which may, in part, contribute to the increment of WAT MCP-1 expression. Fasting plasma triglyceride was higher in the apoCIII treatment group than in the PBS group in both wild-type and TLR2-deficient mice, and fasting plasma glucose and insulin were higher in the apoCIII group than the PBS group only in wild-type mice; these differences were not significant (supplemental Table II ). Systemic administration of apoCIII for 1 week did not affect body weight, food intake, and epididymal WAT weight of both wild-type and TLR2-deficient mice (data not shown).
Discussion
The present study found that apoCIII increased MCP-1 and IL-6 expressions and their production in mouse adipocytes. MCP-1 and IL-6 induce inflammation in many types of cells; and their pathophysiological roles in the development of cardiovascular disease, including atherosclerosis, have been well characterized. 28 In addition, MCP-1 plays a role in the recruitment of macrophages into obese adipose tissue and contributes to the development of obesity. 29 ApoCIII also decreased the expression of adiponectin, which inhibits inflammatory reactions and protects against metabolic disorders and cardiovascular diseases. 30 Thus, apoCIII changed the adipokine expression pattern to proinflammatory and atherogenic, which may, in part, account for its association with cardiovascular disease risk. 9 The present study also showed that apoCIII-rich VLDL increased MCP-1 and IL-6 expressions and decreased adiponectin expression. In contrast, apoCIII-deficient VLDL had a minimal effect on adipokine expression. The effects of apoCIII-rich VLDL were attenuated by anti-apoCIII antibody pretreatment of VLDL. Although apoCIII-rich VLDL is also rich in apoCI and apoE, 4 these apos had no effect on adipokine expression. These results support an interpretation that apoCIII in VLDL directly affects adipokine expression. In addition, apoCIII-rich lipoproteins are rich in lipids. 7 Interestingly, Hiukka et al 31 reported that apoCIII-rich LDL has altered lipid composition that shows susceptibility for sphingomyelinase and increased binding to biglycan. Thus, lipid moieties of apoCIII-rich VLDL may also contribute to the effects on adipokine expression. We confirmed that systemic apoCIII administration induced the expression of MCP-1 and IL-6 in WAT of wild-type mice and increased their plasma levels. In contrast, apoCIII decreased adiponectin expression and its plasma level. These effects seemed to be out of proportion of those of lipid metabolism. ApoCIII also induced macrophage infiltration into WAT, which seems to be mediated by MCP-1. 29 These results support our in vitro observations and suggest the direct role of apoCIII in the consequences of inflammatory adipose tissue, including atherosclerosis. We then tried to elucidate the signaling pathway involved in the effects of apoCIII. In several types of cells, apoCIII activates NF-B, which is a regulator of adipokine expression. 26 NF-B also suppresses PPAR␥ expression, which leads to downregulation of adiponectin. 20 In the present study, apoCIII activated NF-B in 3T3L1 adipocytes; and an NF-B inhibitor attenuated apoCIII-induced adipokine upregulation. These results suggest that the effects of apoCIII were mediated, at least in part, by NF-B. We also examined the involvement of MAP kinases because the NF-B inhibitor did not completely inhibit the apoCIII effects. Several MAP kinases are also involved in the regulation of adipokine upregulation, 27 and researchers 17, 32 reported that apoCIII activates ERK in several types of cells. We found that ERK and NF-B mediate apoCIII-induced adipokine upregulation.
Recent identification of mammalian TLRs as principal sensors of the innate immune system provides a mechanistic link between infection, inflammation, and atherosclerosis. 33 Deficiency of TLR2 in LDL receptor-deficient mice reduced atherosclerosis in the absence of any known exogenous TLR2 agonist, suggesting that some components of dyslipidemia could serve as TLR2 agonists. 33 ApoCIII binds to TLR2 and activates its signaling pathway in monocytes, leading to NF-B activation. 24 Human adipocytes also express functional TLR2 and TLR4. 34 A recent article 35 reports the important roles of TLRs in inflammation in adipocytes, which causes metabolic disorders and atherosclerosis. Stimulation of TLR2 or TLR4 with its agonists activates NF-B p65 in adipocytes and induces proinflammatory adipokine production in human adipose tissue. 36 The present study revealed that apoCIII activates NF-B and ERK through TLR2 in 3T3L1 adipocytes. The effects of apoCIII on adipokine expression were not observed in WAT of TLR2-deficient mice. These results support our in vitro findings that an apoCIII signaling pathway is mediated by TLR2, which may be a novel mechanism by which TLRs mediates proinflammatory adipokine production. In addition, stimulation of TLRs of monocytes/macrophages accelerates their infiltration into adipose tissue, which also causes adipocyte inflammation. 23 Because apoCIII also stimulates monocytes/macrophages through TLR2, 24 the direct effects of apoCIII on monocytes/macrophages may also contribute to the effect of apoCIII on macrophage infiltration into adipose tissue.
ApoCIII is produced by hepatocytes, where its gene is upregulated by several transcription factors, including NF-B and Forkhead box (FOX)-O1. Insulin inhibits FOXO1 activity. 13 Thus, inflammation and insulin resistance stimulate apoCIII production (supplemental Figure V) . MCP-1 and IL-6 induce, and adiponectin protects against, these conditions. 37 Moreover, a recent study 38 showed that the apoCIII gene is expressed in adipocytes. ApoCIII may also affect adipokine expression in an autocrine or paracrine manner. Thus, apoCIII may contribute to the formation of a vicious cycle of inflammation in metabolic disorders. Further investigation will be needed to critically examine the long-term effect of apoCIII on insulin resistance and atherosclerosis.
Clinical studies 14, 15 reported that the serum apoCIII level is elevated in patients with insulin resistance, obesity, or metabolic disorders; and that it is associated with plasma adipokine levels. Our findings suggest that increased serum apo-CIII is not only a clinical manifestation of metabolic disorders but also may exacerbate them through dysregulation of adipokines. ApoCIII may link dyslipidemia to inflammation and atherosclerosis through TLR2. Therefore, apoCIII could be a novel therapeutic target for the "residual risk" in these morbid conditions. 39 
